Epidermal necrolysis after COVID-19 vaccination: An exploratory analysis using World Health Organization VigiBase

Btisseme Ahouach¹, Emmanuelle Diaz¹, Blandine Bertin², Benoit Ben Said^{3

4}, Sandrine Combret⁵, Aurélie Grandvuillemin⁵, Nadine Petitpain⁶, Marie Blanche Rabier⁷, Laure Thomas⁸, Thierry Trenque⁹, Saskia Ingen-Housz-Oro^{1

4

10}, Bénédicte Lebrun-Vignes^{4

10

11}

Affiliations

¹ Dermatology Department, Henri-Mondor Hospital AP-HP, Créteil, France.
² Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon HCL, Lyon, France.
³ Dermatology Department, Edouard Herriot Hospital, Lyon, France.
⁴ Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.
⁵ Pharmacovigilance Department, Dijon University Hospital, Dijon, France.
⁶ Pharmacovigilance Department, Nancy-Brabois Hospital, Vandoeuvre-lès-Nancy, France.
⁷ Pharmacovigilance Department, Besançon University Hospital, Besançon, France.
⁸ Pharmacovigilance Department, Henri-Mondor Hospital AP-HP, Créteil, France.
⁹ Pharmacovigilance Department, University Hospitals of Reims, Reims, France.
¹⁰ Univ Paris Est Créteil Epiderme, UPEC, Créteil, France.
¹¹ Pharmacovigilance Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France.

Btisseme Ahouach et al. J Eur Acad Dermatol Venereol. 2023 Apr.

. 2023 Apr;37(4):e456-e459.

doi: 10.1111/jdv.18845. Epub 2023 Jan 20.

¹ Dermatology Department, Henri-Mondor Hospital AP-HP, Créteil, France.
² Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon HCL, Lyon, France.
³ Dermatology Department, Edouard Herriot Hospital, Lyon, France.
⁴ Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.
⁵ Pharmacovigilance Department, Dijon University Hospital, Dijon, France.
⁶ Pharmacovigilance Department, Nancy-Brabois Hospital, Vandoeuvre-lès-Nancy, France.
⁷ Pharmacovigilance Department, Besançon University Hospital, Besançon, France.
⁸ Pharmacovigilance Department, Henri-Mondor Hospital AP-HP, Créteil, France.
⁹ Pharmacovigilance Department, University Hospitals of Reims, Reims, France.
¹⁰ Univ Paris Est Créteil Epiderme, UPEC, Créteil, France.
¹¹ Pharmacovigilance Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France.

No abstract available

References

1. Darrigade A, Oulès B, Sohier P, Jullie M-L, Moguelet P, Barbaud A, et al. Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: ‘specific’ patterns in a series of 192 patients. Br J Dermatol. 2022;187:615-7.
1. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46-55.
1. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390:1996-2011.
1. Ingen-Housz-Oro S, Duong TA, Bensaid B, Bellon N, de Prost N, Lu D, et al. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis. 2018;13:56.
1. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JNB, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.